Search Results - "Restuccia, E."

VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC) by Huober, J., Barrios, C.H., Niikura, N., Jarzab, M., Chang, Y-C., Huggins-Puhalla, S.L., Graupner, V., Eiger, D., Henschel, V., Gochitashvili, N., Lambertini, C., Restuccia, E., Zhang, H.

Get full text

5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial by Gligorov, J., Pivot, X., Ataseven, B., De Laurentiis, M., Llombart, A., Jung, K.H., Manikhas, A., Azim, H.A., Alexandrou, A., Gupta, K., Herraez-Baranda, L., Tosti, N., Restuccia, E.

Get full text

1816 Preliminary safety results from PERUSE, a study of 1436 patients (pts) treated with first-line pertuzumab (P) combined with trastuzumab (H) and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC) by Miles, D, Puglisi, F, Schneeweiss, A, Ciruelos, E, Peretz-Yablonski, T, Moreno, K, Restuccia, E, Lasserre, S, Bachelot, T

Get full text

A Measurement Plane for Optical Networks to Manage Emergency Events by Tego, E., Carciofi, C., Grazioso, P., Petrini, V., Pompei, S., Matera, F., Attanasio, V., Nastri, E., Restuccia, E.

“…In this work, we show a wide geographical area optical network test bed, adopting the mPlane measurement plane for monitoring its performance and to manage…”
Get full text

1270P IMscin001: Phase Ib dose-finding study of subcutaneous atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) by Burotto, M., Felip, E., Zvirbule, Z., Baranda, L.A. Herraez, Chanu, P., Kshirsagar, S., Maiya, V., Pozzi, E., Restuccia, E.

Get full text

Abstract P6-17-30: Changes in patient, tumor, and treatment characteristics over time in first-line trastuzumab plus taxane (paclitaxel/docetaxel) arms in HER2-positive metastatic breast cancer trials by Badovinac Crnjevic, T, Restuccia, E, Michielin, F, Eng-Wong, J, Nüesch, E

“…Abstract Background: A retrospective analysis showed improved progression-free survival and consistent underestimation of trastuzumab (H) + taxane (T) efficacy…”
Get full text

138P Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab + trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for HER2-positive breast cancer (BC) by Swain, S.M., Tan, A., Gianni, L., Kümmel, S., Dang, C., Schneeweiss, A., O'Shaughnessy, J., Liu, H., Aguila, C., Heeson, S., Macharia, H., Restuccia, E., Loibl, S.

Get full text

1MO The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in Chinese patients (pts) with HER2-positive early breast cancer (EBC): Primary analysis of the phase III, randomised FDChina study by Shao, Z., Huang, T., Fan, Z., Wang, Y., Yan, X., Yang, H., Wang, S., Pang, D., Li, H., Wang, H., Geng, C., Huang, L., Siddiqui, A., Wang, B., Xie, B., Sun, G., Restuccia, E.

Get full text

1206P HER2 copy number variation (CNV), HER2 expression and primary resistance mechanisms in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction cancer (mGC/GEJC) receiving first-line chemotherapy (CT) + trastuzumab (T) +/- pertuzumab (P) in the JACOB trial by Pietrantonio, F., Berrino, E., Manca, P., S.E. Bellomo, Raimondi, A., Corso, S., Morano, F., Migliore, C., Niger, M., Marchiò, C., Di Bartolomeo, M., Restuccia, E., Lambertini, C., Tabernero, J., Giordano, S.

Get full text

1423MO End-of-study analysis from JACOB: A phase III study of pertuzumab (P) + trastuzumab (H) and chemotherapy (CT) in HER2-positive metastatic gastric or gastro-esophageal junction cancer (mGC/GEJC) by Tabernero, J., Hoff, P.M., Shen, L., Ohtsu, A., Shah, M.A., Siddiqui, A., Heeson, S., Wu, H., Restuccia, E., Kang, Y-K.

Get full text

43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial by Dang, C., Ewer, M.S., Delaloge, S., Ferrero, J-M., Colomer, R., de la Cruz Merino, L., Dadswell, K., Verrill, M., Eiger, D., Sarkar, S., de Haas, S., Restuccia, E., Swain, S.M.

Get full text

46P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Safety results from the adjuvant phase of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study by Im, S-A., Tan, A.R., Mattar, A., Colomer, R., Stroyakovskii, D., Nowecki, Z., De Laurentiis, M., Pierga, J-Y., Jung, K.H., Schem, C., Aguila, C., Badovinac Crnjevic, T., Heeson, S., Shivhare, M., Alexandrou, A., Restuccia, E., Jackisch, C.

Get full text

VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up by Loibl, S., Jassem, J., Sonnenblick, A., Parlier, D., Winer, E., Bergh, J., Gelber, R.D., Restuccia, E., Im, Y-H., Huang, C., Dalenc, F., Calvo, I., Procter, M., Caballero, C., Clark, E., Gomez Moreno, H.L., Bliss, J., Viale, G., Bines, J., Piccart, M.

Get full text

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update by Loibl, Sibylle, Jassem, Jacek, Sonnenblick, Amir, Parlier, Damien, Winer, Eric, Bergh, Jonas, Gelber, Richard D, Restuccia, Eleonora, Im, Young-Hyuck, Huang, Chiun-Sheng, Dalenc, Florence, Calvo, Isabel, Procter, Marion, Caballero, Carmela, Clark, Emma, Raimbault, Alice, McConnell, Robin, Monturus, Estefania, de Azambuja, Evandro, Gomez, Henry L, Bliss, Judith, Viale, Giuseppe, Bines, Jose, Piccart, Martine

“…JCO The APHINITY trial (ClinicalTrials.gov identifier: NCT01358877) previously demonstrated that pertuzumab added to adjuvant trastuzumab and chemotherapy…”
Get full text

P009 - 5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial by Gligorov, J., Pivot, X., Ataseven, B., De Laurentiis, M., Llombart, A., Jung, K.H., Manikhas, A., Azim, H.A., Alexandrou, A., Gupta, K., Herraez-Baranda, L., Tosti, N., Restuccia, E.

Get full text

Abstract P4-21-07: Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy in patients ≥65 years with HER2-positive locally recurrent/metastatic breast cancer: Subgroup analyses of the PERUSE study by Miles, D, Schneeweiss, A, Peretz-Yablonski, T, Ciruelos, E, Puglisi, F, Easton, V, Lindegger, N, Restuccia, E, Bachelot, T

“…Abstract Background: First-line (1L) docetaxel+trastuzumab+pertuzumab (THP) is approved for HER2-positive metastatic breast cancer (MBC), based on superior…”
Get full text

Abstract S3-04: Primary analysis of PERTAIN: A randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first-line patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer by Arpino, G, Ferrero, J-M, de la Haba-Rodriguez, J, Easton, V, Schuhmacher, C, Restuccia, E, Rimawi, M

“…Abstract Background: Preclinical and clinical evidence suggest that cross-talk between HER2 and estrogen receptor signaling pathways in breast cancer (BC)…”
Get full text

Abstract P4-21-04: Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (PERUSE) by Bachelot, T, Puglisi, F, Ciruelos, E, Peretz-Yablonski, T, Schneeweiss, A, Easton, V, Lindegger, N, Restuccia, E, Miles, D

“…Abstract Background: First-line (1L) docetaxel+trastuzumab+pertuzumab (THP) for HER2-positive metastatic breast cancer (MBC) significantly improved…”
Get full text

127P Exploratory biomarker (BM) analyses from IMpassion050 by Zhang, H.A., Lambertini, C., Eiger, D., Barrios, C.H., Niikura, N., Jarzab, M., Chang, Y-C., Huggins-Puhalla, S.L., Curran, M., Sarkar, S., Restuccia, E., Huober, J.

Get full text

127P Atezolizumab (A) + pertuzumab + trastuzumab (PH) + chemotherapy (CT) in HER2-positive early breast cancer (HER2+ eBC): Final results of the phase III IMpassion050 trial by Huober, J., Barrios, C.H., Niikura, N., Jarzab, M., Chang, Y-C., Huggins-Puhalla, S.L., Pedrini, J.L., Zhukova, L., Curran, M., Eiger, D., Craine, V., Lambertini, C., Restuccia, E., Zhang, H.

Get full text